ACCG-2671
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
Aconcagua Bio, Inc · Phase 1/2 · Recruiting · Enrollment 164
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Part 1 (SAD) | n/r | n/r | n/r | n/r |
| Placebo Part 1 (SAD) | n/r | n/r | n/r | n/r |
| Part 2 (Food-effect) | n/r | n/r | n/r | n/r |
| ACCG-2671 Part 3 (MAD) | n/r | n/r | n/r | n/r |
| Placebo Part 3 (MAD) | n/r | n/r | n/r | n/r |
Not shown
- Part 1 (SAD): endpoint not reported
- Placebo Part 1 (SAD): endpoint not reported
- Part 2 (Food-effect): endpoint not reported
- ACCG-2671 Part 3 (MAD): endpoint not reported
- Placebo Part 3 (MAD): endpoint not reported